Fig. 2: Functional properties of single cardiomyocytes.
From: Preclinical development of a miR-132 inhibitor for heart failure treatment
a Representative action potential traces of adult ventricular cardiomyocytes derived from wildtype (WT), miR-212/132 transgenic (TG) mice treated with placebo (0.9% NaCl solution) or antimiR-132. b Resting membrane potential (RMP). c Action potential duration at 50% level of repolarization (APD50). d Action potential amplitude. e Upstroke velocity. (WT: n = 18 cells, TG + NaCl: n = 14 cells, TG + antimiR-132: n = 10 cells) f Representative normalized calcium transients. g, Time-to-peak (ttp) of calcium transients at 3 Hz stimulation frequency. (WT: n = 46 cells, TG + NaCl: n = 19 cells/, TG + antimiR-132: n = 26 cells) h Representative normalized sarcomere shortening. i Time-to-peak (ttp) of sarcomeric contraction at 3 Hz stimulation frequency. (WT: n = 52 cells, TG + NaCl: n = 57 cells, TG + antimiR-132: n = 41 cells). j MiR-132 target gene expression in heart tissue (Sarcoplasmic/Endoplasmic Reticulum Ca2+ ATPase 2, Serca2a2). (WT: n = 8, TG + NaCl: n = 7, TG + antimiR-132: n = 5.) Data are mean ± s.e.m; *P < 0.05; **P < 0.01; unpaired two-sided Mann–Whitney U test.
